Trump directs HHS, FDA to require full safety warnings in drug ads
President Trump Sept. 10 signed a memorandum directing the Department of Health and Human Services and Food and Drug Administration to require drug companies to include full safety warnings on their consumer advertisements. HHS and the FDA announced they will remove a loophole from a 1997 provision that allowed drug advertisers to display safety information in a different format or location. Additionally, HHS said the FDA would begin aggressive enforcement of direct-to-consumer violations.
Related News Articles
Headline
The Administration for Strategic Preparedness and Response announced Nov. 3 that it will partner with the Bureau of Industry and Security and the Assistant…
Headline
The Department of Labor Oct. 29 finalized a rule designed to improve transparency of fees collected by pharmacy benefit managers. The rule requires PBMs to…
Headline
The median annual net launch price for new prescription drugs increased 35% from 2022 to 2025, to $257,000, according to a report released by the Institute for…
Headline
A survey released Sept. 10 by the National Comprehensive Cancer Network highlights ongoing shortages of cancer medications. All responding cancer centers…
Headline
The Food and Drug Administration July 10 released a proposed rule that would modernize drug establishment registration requirements, with implications for…
Blog
Digital tools are improving access to behavioral health care at a time when demand is increasing. Individuals can use digital access points to better…